Antibacterial Drugs Market: 2013-2019
Albany, New York (PRWEB) September 09, 2014
An antibacterial drug can be broadly defined as any drug/medicine that inhibits bacterial growth or destroys bacteria in the body. Bacterial infections can often have far reaching health effects on a patient and they show different symptoms based on which doctors choose the best antibacterial drugs (medicines) to treat these infections. However, antibacterial drugs are meant for use against bacteria and viruses, hence they need to be chosen carefully by the medical practitioner.
Antibacterial drugs are categorized under various classes, with each featuring its distinct characteristics. As new bacterial infections continue to be diagnosed b doctors around the world, there is a parallel need for researching, developing, testing and gaining approvals for new antibacterial drug categories. According to a report recently published by U.S.-based market intelligence firm Transparency Market Research, the global market for antibacterial drugs is slated to reach a value of USD 45.09 billion by the end of 2019. This market is likely to show a compounded annual growth rate (CAGR) of 0.3% between 2013 and 2019. The antibacterial drugs market was valued at USD 43.55 billion in 2012.
Browse Full Report Antibacterial Drugs Market Report: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Looking back, the use of antibacterial drugs goes back to 1928 when Alexander Fleming discovered penicillin. Since then, several new antibacterial drugs have been discovered and the market for the same has expanded exponentially. Antibacterial drugs are used for treating infectious diseases that are caused by various types of bacteria including gram positive or gram negative bacteria as well as anaerobic and aerobic bacteria. Such infections cannot be treated using any other methods or substances unlike other diseases that can be inhibited or cured using substitute/alternative methodologies. This factor has been integral antibacterial drugs being an indispensible aspect of medical science and healthcare.
For further inquiries, click here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
- Classification of Antibacterial Drugs
There are seven major classifications of antibacterial drugs. These include: macrolides, aminoglycosides, sulfonamides, β-Lactams, quinolones, phenicols, and tetracyclines. In addition to these, there are several other subcategories of antibacterial drugs that have a small or niche market share.
Within the major antibacterial drugs market, the largest segment constitutes the β-lactams class with a 57% market share as of 2012. The second largest class was that of Quinolones with a 16.6% share in 2012 of the global antibacterial drugs market. However, this market is anticipated to show a negative CAGR between 2013 and 2019. Most of this loss of growth will stem from patent expiries that will lead to sales erosion, as well as the evolution of bacteria strains that are resistant to drugs. At the same time, there are rising concerns among the medical as well as patient fraternity about the higher chances of tendon
damage and tendon rupture resulting from fluoroquinolones therapy.
That having been said, the demand for various other quinolones/fluoroquinolones classes and macrolides will continue to show high growth over the forecast period. The growth rate will largely be sustained due to the need to treat a rising number of infections and launches of new drugs in the pipeline over the next few years.
Browse Antibacterial Drugs Market Article, here: http://www.transparencymarketresearch.com/article/antibacterial-drugs-market.htm
- Growth Drivers for the Antibacterial Drugs Market
Market analysts opine that most of the growth in the antibacterial drugs segment will arise from the high demand for treating infectious diseases as well as the growing need for affordable antibacterial drugs that are also effective. The demand has been growing in regions such as Latin America, Asia-Pacific, Africa, and the Middle East. These regions, thus, have emerged as leading growth drivers for the antibacterial drugs market.
In addition to this, the expanding aging population is considered to be a reason that will indirectly spur a demand for antibacterial drugs across the world. It remains a top priority for pharmaceutical companies to develop innovative molecules that show resistance to various bacteria. As of 2012, the highest revenue share in the antibacterial drugs market was held by Asia-Pacific, and it is not surprising that this region is projected to show the highest growth rate within this segment over the next few years.
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453